Novartis (NVS)
(Delayed Data from NYSE)
$123.86 USD
+0.07 (0.06%)
Updated Nov 3, 2025 04:00 PM ET
After-Market: $124.00 +0.14 (0.11%) 7:52 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVS 123.86 +0.07(0.06%)
Will NVS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.

        
Zacks News for NVS
Here's Why Novartis (NVS) is a Strong Value Stock
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Here's Why Novartis (NVS) is a Strong Momentum Stock
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
Other News for NVS
Cautious Hold on Novartis AG Amid Mixed Ianalumab Data and Valuation Concerns
Trump Offers Help To 'Dilbert' Creator's Cancer Fight
Stochastic Buy Signal appears for NVS after 0.96% move
Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
Is NVS preparing to trend lower? Lower Bollinger Band Walk shows up after advancing 0.67%